Company Search:
Advanced Search
Sponsored Links
Amicus Therapeutics, Inc Company Snapshot
Amicus Therapeutics, Inc operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Amicus Therapeutics, Inc with three other companies in this sector in the United States: Geron Corporation (2014 sales of $1.15 million of which 100% was Diagnostic Products), Opexa Therapeutics, Inc. ($1.27 million of which 100% was Cellular Therapies), and PhaseRx Inc ($1.20 million ).

Sales Analysis. Sales increased substantially in 2014: Amicus Therapeutics, Inc reported sales of $1.22 million for the year ending December of 2014. This represents an increase of 237.2% versus 2013, when the company's sales were $363,000.00 . Despite this increase, sales are still well below the level achieved in 2012, when Amicus Therapeutics, Inc reported sales of $18.41 million.
  Stock Performance Chart for Amicus Therapeutics, Inc
  Stock Data: Recent Stock Performance:
  Current Price (2/17/2017): 6.27
(Figures in U.S. Dollars)
1 Week 1.1%   13 Weeks 17.9%  
4 Weeks -28.3%   52 Weeks -7.4%  
Amicus Therapeutics, Inc Key Data:
  Ticker: FOLD Country: United States
  Exchanges: NAS Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2014 Sales 1,224,000
(Year Ending Jan 2015).
Employees: 185
  Currency: U.S. Dollars Market Cap: 892,385,243
  Fiscal Yr Ends: December Shares Outstanding: 142,326,195
  Share Type: Common Closely Held Shares: 1,208,914
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.